Work

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations

Year: 2022

Type: article

Source: Blood

DOI: 10.1182/blood-2022-164699

Authors: Sarah K Tasian, Deborah S Hunter, I-Ming L Chen, Richard C Harvey, Andrew J. Carroll, Elizabeth Wagner, Shalini C Reshmi, Michael J Borowitz, Brent L. Wood, Jeannie Daniel, Meenakshi Devidas, Elizabeth A. Raetz, Stephen P. Hunger, Albert Assad, Mignon L. Loh

Institutions: Children's Hospital of Philadelphia, Abramson Cancer Center, University of Pennsylvania, Incyte (United States), University of New Mexico, New Mexico Cancer Center, UNM Comprehensive Cancer Center, University of Alabama at Birmingham, Nationwide Children's Hospital, Johns Hopkins University, Johns Hopkins Hospital, Children's Hospital of Los Angeles, St. Jude Children's Research Hospital, NYU Langone Health, New York University, Seattle Children's Hospital

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310117606

FWCI: 3.029

Cites:

Cited by: 18

Related to: 10